AI Article Synopsis
- A comparative study examined patients with Parkinson’s disease and chronic brain ischemia, revealing significant differences in clinical and instrumental data.
- Patients with Parkinson's showed increased molecular markers of endothelial damage similar to those in chronic cerebral ischemia patients.
- Elevated levels of markers like monocyte chemoattractant protein-1, vascular endothelial growth factor, and endothelin-1 could aid in early disease verification before visible symptoms of chronic cerebral ischemia appear.
Article Abstract
A comparative analysis of clinical, instrumental and laboratory data in groups of patients with Parkinson's disease and chronic brain ischemia (stages I-II) was carried out. The information obtained in the groups showed significant differences in clinical and instrumental data that indicated the presence of chronic brain ischemia. A significant increase in molecular markers of endothelial damage comparable with the group of chronic cerebral ischemia was identified in patients with Parkinson's disease. The increase in indicators including monocyte chemoattractant protein-1, vascular endothelial growth factor and endothelin-1 is important for the verification of the disease before the appearance of symptoms of chronic cerebral ischemia in the examined groups of patients.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!